171 related articles for article (PubMed ID: 32274715)
1. Heparanase in Cancer Metastasis - Heparin as a Potential Inhibitor of Cell Adhesion Molecules.
Bendas G; Borsig L
Adv Exp Med Biol; 2020; 1221():309-329. PubMed ID: 32274715
[TBL] [Abstract][Full Text] [Related]
2. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
Hostettler N; Naggi A; Torri G; Ishai-Michaeli R; Casu B; Vlodavsky I; Borsig L
FASEB J; 2007 Nov; 21(13):3562-72. PubMed ID: 17557930
[TBL] [Abstract][Full Text] [Related]
3. Antimetastatic activities of heparins and modified heparins. Experimental evidence.
Borsig L
Thromb Res; 2010 Apr; 125 Suppl 2():S66-71. PubMed ID: 20434009
[TBL] [Abstract][Full Text] [Related]
4. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis.
Borsig L
Semin Thromb Hemost; 2007 Jul; 33(5):540-6. PubMed ID: 17629852
[TBL] [Abstract][Full Text] [Related]
5. Heparins attenuate cancer metastasis: are selectins the link?
Laubli H; Borsig L
Cancer Invest; 2009 Jun; 27(5):474-81. PubMed ID: 19479484
[TBL] [Abstract][Full Text] [Related]
6. Non-Anticoagulant Heparins as Heparanase Inhibitors.
Cassinelli G; Torri G; Naggi A
Adv Exp Med Biol; 2020; 1221():493-522. PubMed ID: 32274724
[TBL] [Abstract][Full Text] [Related]
7. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins.
Bendas G; Borsig L
Int J Cell Biol; 2012; 2012():676731. PubMed ID: 22505933
[TBL] [Abstract][Full Text] [Related]
8. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
9. Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization.
Achour O; Poupard N; Bridiau N; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2016 Jan; 135():316-23. PubMed ID: 26453883
[TBL] [Abstract][Full Text] [Related]
10. Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review).
Kragh M; Loechel F
Int J Oncol; 2005 Oct; 27(4):1159-67. PubMed ID: 16142335
[TBL] [Abstract][Full Text] [Related]
11. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
13. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
14. The impact of heparanese and heparin on cancer metastasis and angiogenesis.
Vlodavsky I; Abboud-Jarrous G; Elkin M; Naggi A; Casu B; Sasisekharan R; Ilan N
Pathophysiol Haemost Thromb; 2006; 35(1-2):116-27. PubMed ID: 16855356
[TBL] [Abstract][Full Text] [Related]
15. Non-anticoagulant heparins and inhibition of cancer.
Casu B; Vlodavsky I; Sanderson RD
Pathophysiol Haemost Thromb; 2008; 36(3-4):195-203. PubMed ID: 19176992
[TBL] [Abstract][Full Text] [Related]
16. The complex effects of heparins on cancer progression and metastasis in experimental studies.
Smorenburg SM; Van Noorden CJ
Pharmacol Rev; 2001 Mar; 53(1):93-105. PubMed ID: 11171940
[TBL] [Abstract][Full Text] [Related]
17. The anti-cancer properties of heparin and its derivatives: a review and prospect.
Ma SN; Mao ZX; Wu Y; Liang MX; Wang DD; Chen X; Chang PA; Zhang W; Tang JH
Cell Adh Migr; 2020 Dec; 14(1):118-128. PubMed ID: 32538273
[TBL] [Abstract][Full Text] [Related]
18. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
19. Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.
Cassinelli G; Dal Bo L; Favini E; Cominetti D; Pozzi S; Tortoreto M; De Cesare M; Lecis D; Scanziani E; Minoli L; Naggi A; Vlodavsky I; Zaffaroni N; Lanzi C
Cancer Lett; 2018 Feb; 415():187-197. PubMed ID: 29225052
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.
Miao HQ; Elkin M; Aingorn E; Ishai-Michaeli R; Stein CA; Vlodavsky I
Int J Cancer; 1999 Oct; 83(3):424-31. PubMed ID: 10495437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
